Senior Management Team
Athol P Haas
Chief Commercial Officer
Athol has worked in C-Suite positions in several industries including biotechnology, creative/digital, food + drink, weapons and defence and telecoms/IT. His diverse background brings a wealth of experience to the commercial and business development of Fixed Phage.
Dr Emma Bell
Principal Research Scientist
With over 12 years’ experience in bacteriophage science Emma is part of the team who originally developed Fixed Phage technology. Following her PhD in bacteriophage ecology Emma did two post-doctorate posts, one of which was for the development of the technology. Emma oversees the science projects within Fixed Phage and ensures customer objectives are fulfilled.
Dr Gordon Smith
Senior Laboratory Scientist
Primary research into novel bacteriophage immobilisation technology. Responsible for the design and implementation of quality systems, experimental design, project management, grant applications, reporting and communication with clients and liaison between shareholders and research staff.
Board of Directors
John has over forty years’ experience of achieving long term value creation and realisation through building technology based enterprises in growth industries. Formerly, he was a Director of Corporate Finance with Hoare Govett in London.
Chief Financial Officer and Company Secretary
Alec acts as Finance Director and Company Secretary through Barwell Consulting Limited. Alec is Managing Director of Barwell Plc and has extensive experience of investing in start-ups and emerging technology companies with high growth potential.
Dr Mike Mattey
Founder and Member of the Scientific Advisory Board
World leading expert in phage research. Founder of Fixed Phage and Inventor of technology.
Dr Trevor Langley
Non-Executive Director and Member of the Scientific Advisory Board
An experienced manager, with an entrepreneurial flair, who has formed a number of start-up bioscience-based product and service companies from scratch. He enjoys the challenges of this environment, particularly working in teams with groups of like-minded individuals.
Non- Executive Director
Jim is co-founder of ChimaeraBio which is a life science specialist investment fund investing on behalf of the Reid family. The fund is managed by Jim and Karen Reid and it has been involved with a number of Scotland’s more successful life science companies including Haptogen (acquired by Wyeth), Qnostics (acquired by BBI plc) and D3 Technologies (acquired by Renishaw plc).
Jim represents the interests of Scottish Investment Bank.